People with Parkinson's Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?

Rebecca J Port, Martin Rumsby, Graham Brown, Ian F Harrison, Anneesa Amjad, Claire J Bale, Rebecca J Port, Martin Rumsby, Graham Brown, Ian F Harrison, Anneesa Amjad, Claire J Bale

Abstract

Background: Parkinson's disease (PD) is a neurodegenerative condition with a diverse and complex pattern of motor and non-motor symptoms which change over time with disease duration.

Objective: The aims of the present study were to discover what symptoms matter most to people with the condition and to examine how these priorities change with disease duration.

Methods: A simple free-text online survey (using SmartSurvey) was developed by Parkinson's UK, which asked participants to identify up to three aspects of the condition they would most like to see improvement in.

Results: 790 people participated reporting 2,295 issues related to PD which were grouped into 24 broad symptom domains. Of these, 1,358 (59.1%) were categorised as motor symptoms, 859 (37.4%) as non-motor issues and 78 (3.4%) as medication problems. This study reveals how certain features of PD become more or less important to patients as the condition progresses. Non-motor symptoms were highly cited from the very earliest stages of PD. Problems with walking, balance and falls, speech problems, freezing and dyskinesia become increasingly important as the condition progresses whereas tremor, stiffness and psychological health become decreasingly important as the condition progresses.

Conclusions: The data suggest that the priorities of people affected by PD for improving life are personal and change with duration of the condition. These findings have implications for developing person-centred management and care, as well as for directing future research to improve quality of life.

Keywords: Parkinson’s disease; patient priorities; progression; quality of life; symptoms.

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 3
Fig. 3
Symptoms of Parkinson’s disease that were reported as a priority for improvement less frequently with disease duration. Percentages show the respondents with a duration of n = 134), 2–5 years (n = 313), 6–10 years (n = 209) and 11 + years (n = 126) reporting (a) tremor, (b) stiffness, and (c) psychological health within their 3 priority areas. Statistical significant between duration groups (Dunn’s multiple comparisons tests) are presented as asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Responses from bereaved partners, family members or friends have been excluded as no duration data is available.
Fig. 4
Fig. 4
Symptoms or side effects of Parkinson’s disease that were reported as a priority for improvement more frequently with disease duration. Percentages show the respondents with a duration of n = 134), 2–5 years (n = 313), 6–10 years (n = 209) and 11 + years (n = 126) reporting (a) balance and falls, (b) walking, (c) speech, (d) freezing, (e) dyskinesia, and (f) medication wearing-off within their 3 priority areas. Statistical significant between duration groups (Dunn’s multiple comparisons tests) are presented as asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Responses from bereaved partners, family members or friends have been excluded as no duration data is available.
Fig. 1
Fig. 1
Symptoms or side effects reported in response to the question “what aspect of Parkinson’s do you most wish to see improvement in?” presented by priority. Percentages show the relative frequency of symptoms or side effects reported within primary responses (n = 848), secondary responses (n = 779), and tertiary responses (n = 668).
Fig. 2
Fig. 2
Top 10 most frequently reported symptoms or side effects respondents wished to see an improvement in by disease duration. The area of the boxes show the relative frequency of the 10 most reported symptoms or side effects respondents diagnosed for (a) n = 409), (b) 2–5 years (n = 648), (c) 5–10 years (n = 327) and (d) 11 + years (n = 86), wished to see an improvement in, where n is the total number of categorizable, symptoms or side effects reported. Responses from bereaved partners, family members or friends have been excluded as no duration data is available.

References

    1. Parkinson’s UK (2017) The incidence and prevalence of Parkinson’s in the UK, Parkinson’s UK website, , Posted January 8, 2018, Accessed July 30, 2020.
    1. Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, Frank MJ, Jahanshahi M (2016) Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev 68, 727–740.
    1. Chaudhuri KR, Healy DG, Schapira AHV (2006) Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol 5, 235–245.
    1. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386, 896–912.
    1. Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17, 427–442.
    1. Vu TC, Nutt JG, Holford NH (2012) Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. Br J Clin Pharmacol 74, 267–83.
    1. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2005) Progression of motor impairment and disability in Parkinson disease: A population-based study. Neurology 65, 1436–1441.
    1. Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49, 328–338.
    1. Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM (2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89, 1279–1287.
    1. Deane KHO, Flaherty H, Daley DJ, Pascoe R, Penhale B, Clarke CE, Sackley C, Storey S (2014) Priority setting partnership to identify the top 10 research priorities for the management of Parkinson’s disease. BMJ Open 4, e006434.
    1. Mursaleen LR, Stamford JA, Butterfield T, Edwards G, Kustow P, Kustow PA, Griffith S, Dudgeon GMK, Dudgeon MG (2017) Descriptive symptom terminology used by Parkinson’s patients and caregivers. J Parkinsonism Restless Legs Syndr 7, 71–78.
    1. Martinez-Martin P (2011) The importance of non-motor disturbances to quality of life in Parkinson’s disease. J Neurol Sci 310, 12–16.
    1. Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M (2011) Non motor versus motor symptoms: How much do they matter to health status in Parkinson’s disease? Mov Disord 2, 236–241.
    1. Uebelacker A, Epstein-Lubow G, Lewis T, Broughton MK, Friedman JH (2014) A survey of Parkinson’s disease patients: Most bothersome symptoms and coping preferences. J Parkinsons Dis 4, 717–723.
    1. Politis M, Wu K, Molloy S, Bain GP, Chaudhuri KR, Piccini P (2010) Parkinson’s disease symptoms: The patient’s perspective. Mov Disord 25, 1646–1651.
    1. Hermanowicz N, Castillo-Shell M, McMean A, Fishman J, D’Souza J (2019) Patient and physician perceptions of disease management in Parkinson’s disease: Results from a US-based multicenter survey. Neuropsychiatr Dis Treat 15, 1487–1495.
    1. Heusinkveld LE, Hacker ML, Turchan M, Davis TL, Charles D (2018) Impact of tremor on patients with early stage Parkinson’s disease. Front Neurol 9, 628.
    1. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD; PRIAMO study group (2009) Amulticenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24, 1641–1649.
    1. Gallagher DA, Lees AJ, Schrag A (2010) What are the most important non-motor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25, 2493–2500.
    1. Lee HM, Koh SB (2015) Many faces of Parkinson’s disease: Non-motor symptoms of Parkinson’s disease. Mov Disord 8, 92–97.
    1. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson’s Progression Markers Initiative (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 30, 919–27.
    1. Siciliano M, Trojano L, Santangelo G, De Micco R, Tedeschi G, Tessitore A (2018) Fatigue in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 33, 1712–1723.
    1. Chahine LM, Amara AW, Videnovic A (2017) A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med Rev 35, 33–50.
    1. McLean G, Hindle JV, Guthrie B, Mercer SW (2017) Co-morbidity and polypharmacy in Parkinson’s disease: Insights from a large Scottish primary care database. BMC Neurol 17, 126.
    1. Shin JY, Pohlig RT, Habermann B (2017) Self-reported symptoms of Parkinson’s disease by sex and disease duration. West J Nurs Res 39, 1412–1428.
    1. Mathur S, Mursaleen L, Stamford J, DeWitte S, Robledo I, Isaacs T (2017) Challenges of improving patient-centred care in Parkinson’s disease. J Parkinsons Dis 7, 163–174.

Source: PubMed

3
Subskrybuj